MA29636B1 - Dérivés de l'isoquinolone substitués par pipéridinyle en tant qu'inhibiteur de la Rho-kinase - Google Patents

Dérivés de l'isoquinolone substitués par pipéridinyle en tant qu'inhibiteur de la Rho-kinase

Info

Publication number
MA29636B1
MA29636B1 MA30583A MA30583A MA29636B1 MA 29636 B1 MA29636 B1 MA 29636B1 MA 30583 A MA30583 A MA 30583A MA 30583 A MA30583 A MA 30583A MA 29636 B1 MA29636 B1 MA 29636B1
Authority
MA
Morocco
Prior art keywords
rho
kinase inhibitor
piperidinyl substituted
isoquinolone derivatives
derivatives
Prior art date
Application number
MA30583A
Other languages
English (en)
Inventor
Oliver Plettenburg
Armin Hofmeister
Dieter Kadereit
Joachim Brendel
Matthias Loehn
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA29636B1 publication Critical patent/MA29636B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)

Abstract

L'invention concerne des dérivés de l'isoquinolone de formule (I) ou des dérivés de l'isoquinoline de formule (l') substitués en 6-pipéridinyl, utiles pour la prévention et/ou le traitement de maladies associées à la Rho-kinase et/ou à la phosphorylation de la phosphatase à chaîne légère de la myosine par l'intermédiaire de la Rho-kinase, et des compositions qui contiennent de tels composants.
MA30583A 2005-07-26 2008-01-18 Dérivés de l'isoquinolone substitués par pipéridinyle en tant qu'inhibiteur de la Rho-kinase MA29636B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05016154 2005-07-26

Publications (1)

Publication Number Publication Date
MA29636B1 true MA29636B1 (fr) 2008-07-01

Family

ID=34979095

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30583A MA29636B1 (fr) 2005-07-26 2008-01-18 Dérivés de l'isoquinolone substitués par pipéridinyle en tant qu'inhibiteur de la Rho-kinase

Country Status (32)

Country Link
US (1) US8188117B2 (fr)
EP (2) EP2385047B1 (fr)
JP (1) JP5060478B2 (fr)
KR (1) KR101373535B1 (fr)
CN (1) CN101228149B (fr)
AR (1) AR054868A1 (fr)
AU (1) AU2006274245B2 (fr)
BR (1) BRPI0613861B8 (fr)
CA (1) CA2615577C (fr)
CR (1) CR9603A (fr)
DK (1) DK1910333T3 (fr)
DO (1) DOP2006000178A (fr)
EC (1) ECSP088135A (fr)
ES (1) ES2423006T3 (fr)
GT (1) GT200600328A (fr)
HK (1) HK1123035A1 (fr)
IL (1) IL188702A (fr)
MA (1) MA29636B1 (fr)
MX (1) MX2008001053A (fr)
MY (1) MY148479A (fr)
NI (1) NI200800025A (fr)
NO (1) NO341888B1 (fr)
NZ (1) NZ565668A (fr)
PE (1) PE20070217A1 (fr)
PT (1) PT1910333E (fr)
RU (1) RU2414467C2 (fr)
TN (1) TNSN08039A1 (fr)
TW (1) TWI383979B (fr)
UA (1) UA93882C2 (fr)
UY (1) UY29697A1 (fr)
WO (1) WO2007012421A1 (fr)
ZA (1) ZA200710951B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008000017A (es) 2005-06-28 2008-03-26 Sanofi Aventis Derivados de isoquinolina como inhibidores de rho-cinasa.
MX2008000956A (es) 2005-07-26 2008-03-27 Sanofi Aventis Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa.
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
MX2009002685A (es) * 2006-09-11 2009-10-13 Organon Nv Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).
JP5405316B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノリン誘導体
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos
PT2102164E (pt) 2006-12-27 2011-01-21 Sanofi Aventis Derivados de isoquinolina e de isoquinolinona substituída com cicloalquilamina
AU2007338408B2 (en) 2006-12-27 2012-07-26 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
MY155009A (en) 2006-12-27 2015-08-28 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
BRPI0720862A2 (pt) 2006-12-27 2014-02-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008091555A2 (fr) * 2007-01-22 2008-07-31 Gtx, Inc. Agents se liant aux récepteurs nucléaires
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
KR20100103646A (ko) * 2007-12-26 2010-09-27 사노피-아벤티스 ６­치환된­１­（２ｈ）­이소퀴놀리논의 제조 방법
JP5713893B2 (ja) 2008-06-24 2015-05-07 サノフイ Ｒｈｏ−キナーゼ阻害剤としての置換イソキノリン類及びイソキノリノン類
EP2303845B1 (fr) 2008-06-24 2013-09-18 Sanofi Isoquinoléine substituée bi- et polycyclique et dérivés d'isoquinoléine utilisées comme inhibiteurs de la rho-kinase
CN102131785B (zh) 2008-06-24 2014-10-29 赛诺菲-安万特 6-取代的异喹啉和异喹啉酮
US9865233B2 (en) 2008-12-30 2018-01-09 Intel Corporation Hybrid graphics display power management
MX2012004289A (es) * 2009-10-13 2012-06-12 Msd Oss Bv Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina.
EP2729007A1 (fr) * 2011-07-04 2014-05-14 Bayer Intellectual Property GmbH Utilisation d'isoquinoléinones, d'isoquinoléinediones, d'isoquinoléinetriones et de dihydroisoquinoléinones substituées ou de leurs sels comme principes actifs contre le stress abiotique des plantes
KR102013566B1 (ko) * 2011-07-08 2019-08-23 사노피 ６-(피페리딘-４-일옥시)-２ｈ-이소퀴놀린-１-온 하이드로클로라이드의 결정성 용매화물
US8598201B2 (en) * 2011-07-08 2013-12-03 Sanofi Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
BR112014000279B1 (pt) 2011-07-08 2020-11-24 Sanofi composto de fenila substituído de fórmula (vi), seu processo de preparação, seu uso na preparação de um composto de fórmula (i) e processo de preparação de um composto de fórmula (i)
EP3141235A1 (fr) 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N- (6- ((2r, 3s) -3,4-dihydroxybutan-2-yloxy) -2- (4-fluorobenzylthio) pyrimidin-4-yl) -3-methylazetidine-l sulfonamide
PL3640241T3 (pl) 2013-10-18 2022-12-05 Celgene Quanticel Research, Inc. Inhibitory bromodomeny
WO2015074064A2 (fr) 2013-11-18 2015-05-21 Bair Kenneth W Compositions de tétrahydroquinoline utilisées comme inhibiteurs de protéines à bromodomaine et domaine extraterminal (bet)
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2017003723A1 (fr) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et leurs utilisations
WO2017174879A1 (fr) * 2016-04-06 2017-10-12 University Of Oulu Composés pour utilisation dans le traitement du cancer
JP2019513804A (ja) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN106632258B (zh) * 2016-12-15 2019-04-02 三峡大学 四氢异喹啉-2-基芳氧基苯氧基烷基酮化合物及其应用
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11738030B2 (en) 2021-10-30 2023-08-29 Aneuryst, Inc. Treatments for disturbed cerebral homeostasis
WO2024030854A1 (fr) * 2022-08-01 2024-02-08 Valo Health, Inc. Procédé de préparation de 1-(2h)-isoquinolinones substituées en position 6 et composé intermédiaire

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
WO1992002476A1 (fr) 1990-07-31 1992-02-20 E.I. Du Pont De Nemours And Company Equilibrage catalytique d'halocarbones selectionnes
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
EP1007525A1 (fr) 1997-08-29 2000-06-14 Zeneca Limited Derives aminometyl-oxo-oxazolidinyl-benzene
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
HUP0204496A3 (en) 2000-01-20 2004-07-28 Eisai Co Ltd Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
AU2001296008A1 (en) 2000-10-27 2002-05-06 Takeda Chemical Industries Ltd. Process for preparing substituted aromatic compounds and intermediates therefor
WO2002055496A1 (fr) 2001-01-15 2002-07-18 Glaxo Group Limited Derives aryle de piperidine et de piperazine comme inducteurs de l'expression du recepteur ldl
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
EP1389194A2 (fr) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
EP1403255A4 (fr) * 2001-06-12 2005-04-06 Sumitomo Pharma Inhibiteurs de rho kinase
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (fr) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement des maladies a prions
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
WO2004009555A1 (fr) 2002-07-22 2004-01-29 Asahi Kasei Pharma Corporation Derive d'isoquinoline 5-substituee
CN100383140C (zh) 2002-09-12 2008-04-23 麒麟麦酒株式会社 具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂
WO2004105757A2 (fr) 2003-05-29 2004-12-09 Schering Aktiengesellschaft Utilisation des inhibiteurs de la rho kinase dans le traitement de l'anevrisme et de l'hypertrophie cardiaque
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2004275720B2 (en) 2003-09-23 2008-04-24 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
JP4718467B2 (ja) 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
EP1671962A1 (fr) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique fondu et utilisation correspondante
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
EP1689719A1 (fr) 2003-11-25 2006-08-16 Eli Lilly And Company Derives de 7-phenyl-isoquinoline-5-sulfonylamino en tant qu'inhibiteurs de akt (proteine kinase b)
WO2005074535A2 (fr) 2004-01-30 2005-08-18 Eisai Co., Ltd. Inhibiteurs de cholinesterase pour des troubles de la colonne vertebrale
EP1729761A4 (fr) 2004-03-05 2008-09-03 Eisai Co Ltd Traitement de cadasil avec des inhibiteurs de la cholinesterase
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
MX2008000956A (es) 2005-07-26 2008-03-27 Sanofi Aventis Derivados de ciclohexilaminisoquinolona en calidad de inhibidores de rho-quinasa.
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
PT2102164E (pt) 2006-12-27 2011-01-21 Sanofi Aventis Derivados de isoquinolina e de isoquinolinona substituída com cicloalquilamina
BRPI0720909A2 (pt) 2006-12-27 2016-11-01 Sanofi Aventis derivados de isoquinolina e isoquinolinona substituídos

Also Published As

Publication number Publication date
EP1910333A1 (fr) 2008-04-16
US8188117B2 (en) 2012-05-29
TWI383979B (zh) 2013-02-01
ECSP088135A (es) 2008-02-20
NZ565668A (en) 2010-09-30
ZA200710951B (en) 2008-08-27
EP2385047B1 (fr) 2013-05-29
AU2006274245B2 (en) 2011-11-24
BRPI0613861A2 (pt) 2011-02-15
MY148479A (en) 2013-04-30
AR054868A1 (es) 2007-07-25
NI200800025A (es) 2009-03-03
BRPI0613861B8 (pt) 2021-05-25
ES2423006T3 (es) 2013-09-17
NO20080963L (no) 2008-04-02
CR9603A (es) 2008-03-06
GT200600328A (es) 2007-02-22
IL188702A0 (en) 2008-08-07
CN101228149A (zh) 2008-07-23
TNSN08039A1 (en) 2009-07-14
EP1910333B1 (fr) 2013-05-22
PE20070217A1 (es) 2007-03-19
MX2008001053A (es) 2008-03-19
KR20080028971A (ko) 2008-04-02
RU2414467C2 (ru) 2011-03-20
UY29697A1 (es) 2007-02-28
DK1910333T3 (da) 2013-08-19
UA93882C2 (ru) 2011-03-25
RU2008106950A (ru) 2009-09-10
IL188702A (en) 2012-12-31
EP2385047A1 (fr) 2011-11-09
JP5060478B2 (ja) 2012-10-31
KR101373535B1 (ko) 2014-03-12
DOP2006000178A (es) 2007-02-15
CA2615577C (fr) 2014-09-09
US20090093518A1 (en) 2009-04-09
CA2615577A1 (fr) 2007-02-01
AU2006274245A1 (en) 2007-02-01
TW200918520A (en) 2009-05-01
WO2007012421A1 (fr) 2007-02-01
CN101228149B (zh) 2013-01-02
BRPI0613861B1 (pt) 2019-12-10
JP2009502829A (ja) 2009-01-29
PT1910333E (pt) 2013-08-01
NO341888B1 (no) 2018-02-12
HK1123035A1 (en) 2009-06-05

Similar Documents

Publication Publication Date Title
MA29636B1 (fr) Dérivés de l'isoquinolone substitués par pipéridinyle en tant qu'inhibiteur de la Rho-kinase
MA29639B1 (fr) Derives de cyclohexylamine isoquinolone en tant qu'inhibiteurs de la rhokinase.
MA31021B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees en tant qu'inhibiteurs de la rho-kinase
MA29535B1 (fr) Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
MA31075B1 (fr) Dérivés d'isoquinolone substitués par une cycloalkylamine.
MA31022B1 (fr) Derives de l'isoquinoleine et de l'isoquinoleinone substituees
MA31024B1 (fr) Nouveaux derives de l'isoquinoleine et de l'isoquinoleinone substituees
MA31076B1 (fr) Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine.
MA31023B1 (fr) Derives de l'isoquinolone et de l'isoquinoleinone substituees par une cycloalkylamine
SV2009003317A (es) Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa
MA32401B1 (fr) Derives d'isoquinoleine et d'isoquinoleinone substitues bi-et polycycliques
UY29698A1 (es) Derivados de ciclohexilaminisoquinolona